Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Crame.

Yesterday, March 10, 2015, 98 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,617.00 to $5,999,989.08.

Highlighted Stocks Traded by Insiders:

Alon USA Energy (ALJ) - FREE Research Report

Morris Jeff D, who is Vice Chairman of the Board at Alon USA Energy, sold 25,000 shares at $14.15 on March 10, 2015. Following this transaction, the Vice Chairman of the Board owned 1.1 million shares meaning that the stake was reduced by 2.31% with the 25,000-share transaction.

The shares most recently traded at $13.99, down $0.16, or 1.14% since the insider transaction. Historical insider transactions for Alon USA Energy go as follows:

  • 4-Week # shares sold: 3.8 million
  • 12-Week # shares bought: 4,000
  • 12-Week # shares sold: 3.8 million
  • 24-Week # shares bought: 4,000
  • 24-Week # shares sold: 4.3 million

The average volume for Alon USA Energy has been 1.1 million shares per day over the past 30 days. Alon USA Energy has a market cap of $1.0 billion and is part of the basic materials sector and energy industry. Shares are up 11.44% year-to-date as of the close of trading on Tuesday.

Alon USA Energy, Inc. operates as an independent refiner and marketer of petroleum products primarily in the South Central, Southwestern, and the Western regions of the United States. The company operates in three segments: Refining and Marketing, Asphalt, and Retail. The stock currently has a dividend yield of 2.77%. The company has a P/E ratio of 26.2. Currently, there is 1 analyst who rates Alon USA Energy a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALJ - FREE

TheStreet Quant Ratings

rates Alon USA Energy as a

hold

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and notable return on equity. However, as a counter to these strengths, we also find weaknesses including relatively poor performance when compared with the S&P 500 during the past year, weak operating cash flow and poor profit margins. Get the full

Alon USA Energy Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Lannett (LCI) - FREE Research Report

Taveira Paul, who is Director at Lannett, sold 2,000 shares at $68.09 on March 10, 2015. Following this transaction, the Director owned 18,000 shares meaning that the stake was reduced by 10% with the 2,000-share transaction.

The shares most recently traded at $63.85, down $4.24, or 6.64% since the insider transaction. Historical insider transactions for Lannett go as follows:

  • 4-Week # shares bought: 1,250
  • 4-Week # shares sold: 104,000
  • 12-Week # shares bought: 1,250
  • 12-Week # shares sold: 123,216
  • 24-Week # shares bought: 2,250
  • 24-Week # shares sold: 178,216

The average volume for Lannett has been 752,700 shares per day over the past 30 days. Lannett has a market cap of $2.3 billion and is part of the health care sector and drugs industry. Shares are up 47.76% year-to-date as of the close of trading on Tuesday.

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of branded pharmaceutical products in the United States. It offers solid oral, extended release, topical, and oral solution finished dosage forms of drugs that address a range of therapeutic areas. The company has a P/E ratio of 18.7. Currently, there are 2 analysts who rate Lannett a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on LCI - FREE

TheStreet Quant Ratings

rates Lannett as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Lannett Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

US Physical Therapy (USPH) - FREE Research Report

Trier Clayton, who is Director at US Physical Therapy, sold 3,250 shares at $45.05 on March 10, 2015. Following this transaction, the Director owned 13,000 shares meaning that the stake was reduced by 20% with the 3,250-share transaction.

The shares most recently traded at $45.48, up $0.43, or 0.95% since the insider transaction. Historical insider transactions for US Physical Therapy go as follows:

  • 4-Week # shares bought: 250
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 250
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 250
  • 24-Week # shares sold: 63,873

The average volume for US Physical Therapy has been 50,600 shares per day over the past 30 days. US Physical Therapy has a market cap of $552.3 million and is part of the health care sector and health services industry. Shares are up 7.6% year-to-date as of the close of trading on Tuesday.

U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics in the United States. The stock currently has a dividend yield of 1.33%. The company has a P/E ratio of 26.3. Currently, there are 2 analysts who rate US Physical Therapy a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on USPH - FREE

TheStreet Quant Ratings

rates US Physical Therapy as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full

US Physical Therapy Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null